Details for Patent: 8,889,176
✉ Email this page to a colleague
Which drugs does patent 8,889,176 protect, and when does it expire?
Patent 8,889,176 protects LAZANDA and is included in one NDA.
This patent has thirty-five patent family members in twenty-four countries.
Summary for Patent: 8,889,176
| Title: | Method of managing or treating pain |
| Abstract: | A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (C.sub.max) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed. |
| Inventor(s): | Watts; Peter James (Nottingham, GB), Castile; Jonathan David (Nottingham, GB), Lafferty; William Columbus (Leicester, GB), Smith; Alan (Nottingham, GB) |
| Assignee: | Depomed, Inc. (Newark, CA) |
| Application Number: | 13/541,314 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 8,889,176
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-001 | Jun 30, 2011 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER | ⤷ Try a Trial | ||||
| Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-002 | Jun 30, 2011 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,889,176
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0300531.1 | Jan 10, 2003 |
International Family Members for US Patent 8,889,176
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2004204381 | ⤷ Try a Trial | |||
| Brazil | PI0406674 | ⤷ Try a Trial | |||
| Canada | 2511974 | ⤷ Try a Trial | |||
| China | 100423709 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
